Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 652 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... November 26, 2019 Conducting Phase I Clinical Trials During the COVID-19 Pandemic August 5, 2020 Cancer in My Community: Overcoming Inequities in Care in Argentina January 3, 2023 The most important cancer research stories of 2022 December 14, 2022 Load more HOT NEWS Popular Fitness Blogger Maria Kang Removed Her Breast Implants Due To... Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... The Barriers to Care Faced by LGBTQ People With Cancer: An... World Cancer Day 2023: where does the UK stand?
